Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 14/20 | 0.36 |
| ▸ | PIK3R1 | P27986 | 13/20 | 0.36 |
| ▸ | MTOR | P42345 | 1/20 | 0.35 |
| ▸ | DPP4 | P27487 | 4/20 | 0.35 |
| ▸ | MAP3K12 | Q12852 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25908431 | 0.78 | PIK3CA (0.42) | PIK3CAMTORMAP3K12 | |
| SCHEMBL25908428 | 0.77 | MAP3K12 (0.44) | PIK3CAPIK3R1MAP3K12 | |
| SCHEMBL25908430 | 0.77 | MAP3K12 (0.44) | PIK3CAPIK3R1MAP3K12 | |
| SCHEMBL24962176 | 0.76 | RAD52 (0.42) | PIK3CADPP4MAP3K12 | |
| SCHEMBL25908456 | 0.76 | PDE10A (0.51) | PIK3CADPP4MAP3K12 | |
| SCHEMBL25908455 | 0.74 | DPP4 (0.40) | PIK3CAPIK3R1DPP4MAP3K12 | |
| SCHEMBL25908374 | 0.74 | KCNN3 (0.35) | — | |
| SCHEMBL25908373 | 0.73 | PDE10A (0.51) | — | |
| SCHEMBL24962187 | 0.70 | ATR (0.38) | MTORDPP4MAP3K12 | |
| SCHEMBL24962177 | 0.69 | RAD52 (0.40) | DPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250101040-A1 | NEW TYPE PYRAZOLOPYRIMIDINE COMPOUND AND COMPOSITION THEREOF, PREPARATION METHOD THEREFOR AND USE THEREOF | Jiangsu Yayo Biotechnology Co., Ltd. (CN) | 2025-03-27 | — | — | US | disclosed |
| EP-4467545-A1 | NEW TYPE PYRAZOLOPYRIMIDINE COMPOUND AND COMPOSITION THEREOF, PREPARATION METHOD THEREFOR AND USE THEREOF | Jiangsu Yayo Biotechnology Co. Ltd (CN) | 2024-11-27 | — | — | EP | disclosed |
| WO-2023138343-A1 | NEW TYPE PYRAZOLOPYRIMIDINE COMPOUND AND COMPOSITION THEREOF, PREPARATION METHOD THEREFOR AND USE THEREOF | 江苏亚尧生物科技有限公司 | 2023-07-27 | — | — | WO | disclosed |
| WO-2023138343-A1 | NEW TYPE PYRAZOLOPYRIMIDINE COMPOUND AND COMPOSITION THEREOF, PREPARATION METHOD THEREFOR AND USE THEREOF | 江苏亚尧生物科技有限公司 | 2023-07-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250101040-A1 | NEW TYPE PYRAZOLOPYRIMIDINE COMPOUND AND COMPOSITION THEREOF, PREPARATION METHOD THEREFOR AND USE THEREOF | WEE1, ATR, WEE2 | PIK3CA 60/4885PIK3R1 434/4885MTOR 1638/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.